CD19 / Vio Bright R720 / REA749
Product Details
Description | Clone REA749 recognizes the mouse CD19 antigen, a type I transmembrane glycoprotein expressed on B cells throughout their development from the early pro–B cell through the mature B cell stages. Its expression is down-regulated during terminal differentiation to plasma cells. CD19 associates with complement receptor CD21 and with CD81 on the cell surface of mature B cells, thereby forming a multi-molecular complex which signals synergistically to membrane IgM. It is also expressed on follicular dendritic cells and peritoneal mast cells. | Additional information: Clone REA749 displays negligible binding to Fc receptors. | |
---|---|---|
Conjugate | Vio Bright R720 | |
Clone | REA749 | |
Target Species | Mouse | |
Applications | FC | |
Supplier | Miltenyi Biotec | |
Catalog # | Sign in to view product details, citations, and spectra | |
Size | ||
Price | ||
Antigen | ||
Host | ||
Isotype |
About CD19
This gene encodes a member of the immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains separated by a non-Ig-like domain, a hydrophobic transmembrane domain, and a large C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia, an inability to mount an antibody response to antigen, and recurrent bacterial infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020]
This gene encodes a member of the immunoglobulin gene superfamily. Expression of this cell surface protein is restricted to B cell lymphocytes. This protein is a reliable marker for pre-B cells but its expression diminishes during terminal B cell differentiation in antibody secreting plasma cells. The protein has two N-terminal extracellular Ig-like domains separated by a non-Ig-like domain, a hydrophobic transmembrane domain, and a large C-terminal cytoplasmic domain. This protein forms a complex with several membrane proteins including complement receptor type 2 (CD21) and tetraspanin (CD81) and this complex reduces the threshold for antigen-initiated B cell activation. Activation of this B-cell antigen receptor complex activates the phosphatidylinositol 3-kinase signalling pathway and the subsequent release of intracellular stores of calcium ions. This protein is a target of chimeric antigen receptor (CAR) T-cells used in the treatment of lymphoblastic leukemia. Mutations in this gene are associated with the disease common variable immunodeficiency 3 (CVID3) which results in a failure of B-cell differentiation and impaired secretion of immunoglobulins. CVID3 is characterized by hypogammaglobulinemia, an inability to mount an antibody response to antigen, and recurrent bacterial infections. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jul 2020]
About Vio Bright R720
Vio® Bright R720 and Vio® R720 have an excitation peak at 695 nm and an emission peak at 720 nm, which means that these dyes are optimally excited by the 640 nm red laser while the emitted light is collected by the channel with a 725/40 bandpass filter. Miltenyi Biotec's proprietary multimerization technology allows for Vio® Bright R720 to be nearly twice the brightness of Vio® R720, so this choice of fluorophore offers flexibility in your panel design in flow cytometry. Spectrally, Vio® Bright R720 is comparable to R700 from BD Biosciences.
Vio® Bright R720 and Vio® R720 have an excitation peak at 695 nm and an emission peak at 720 nm, which means that these dyes are optimally excited by the 640 nm red laser while the emitted light is collected by the channel with a 725/40 bandpass filter. Miltenyi Biotec's proprietary multimerization technology allows for Vio® Bright R720 to be nearly twice the brightness of Vio® R720, so this choice of fluorophore offers flexibility in your panel design in flow cytometry. Spectrally, Vio® Bright R720 is comparable to R700 from BD Biosciences.
Experiment Design Tools
Panel Builders
Looking to design a Microscopy or Flow Cytometry experiment?
Validation References
Reviews & Ratings
Reviews |
---|
Looking for more options?
3840 CD19 antibodies from over 56 suppliers available with over 217 conjugates.